转自：智通财经 【创新药概念震荡反弹 广生堂涨近15%】智通财经1月23日电，创新药概念盘中震荡反弹，广生堂涨近 15%，海特生物、昭衍新药、美迪西、舒泰神、一品红等跟涨。消息面上，2026年1月22日，由国家科 技重大专项支持的"慢性乙型肝炎临床治愈联合治疗新方案研究"召开，广生堂药业旗下创新药子公司广 生中霖生物科技携旗下核心创新药GST-HG131、GST-HG141及其联合治疗方案，正式纳入国家科技重 大专项课题研究体系。 ...

Market Performance - The recombinant protein sector declined by 0.62%, ranking among the top losers in the concept sectors, with *ST WanFang hitting the daily limit down [1] - Notable declines in the sector included Aladdin, Zexing Pharmaceutical, and Shutaishen, while 18 stocks within the sector saw price increases, with Haitai Biological, Yabao Pharmaceutical, and Zhongyuan Qihe leading with gains of 4.28%, 1.17%, and 1.08% respectively [1] Capital Flow - The recombinant protein sector experienced a net outflow of 479 million yuan, with 41 stocks seeing net outflows, and 6 stocks with outflows exceeding 30 million yuan [1] - The stock with the highest net outflow was Xilong Science, with a net outflow of 59.20 million yuan, followed by Aladdin, Shutaishen, and Aimeike with outflows of 50.46 million yuan, 39.78 million yuan, and 39.10 million yuan respectively [1] Top Gainers and Losers - The top gainers in the recombinant protein sector included Haitai Biological, with a gain of 4.28%, and the top losers included Aladdin and Shutaishen, with declines of 6.46% and 2.49% respectively [1][2] - Other notable stocks with significant capital inflows included Haitai Biological, Huayu Pharmaceutical, and Tonghua Dongbao, with net inflows of 17.77 million yuan, 15.97 million yuan, and 9.97 million yuan respectively [3]

Core Viewpoint - The innovative drug sector is expected to experience a resurgence in 2025, transitioning from a broad market rally to a focus on select stocks driven by global clinical data, overseas commercialization, and domestic profitability turning points [1] Group 1: Market Performance - In 2025, the A-share innovative drug index saw an annual increase of nearly 20%, while the H-share index rose by 66.52%. The first half of the year recorded increases of approximately 17% for A-shares and 58% for H-shares, with the second half showing more modest gains of about 3% and 9% respectively [1] - The A-share billion-dollar club includes companies like BeiGene (市值4190.64亿元), Hengrui Medicine (市值3994.27亿元), and Baillie Gifford (市值1332.18亿元), while the H-share club includes Hengrui Medicine (市值4729.34亿元), BeiGene (市值3191亿元), and others [2] Group 2: Company Dynamics - Companies in the billion-dollar club are valued based on "pipeline value + BD monetization + global sales peak." Capital markets are comparing these firms to global leaders, elevating them from "First-in-class" to "Best-in-class" [3] - In 2025, domestic innovative drug license-out transactions totaled 83, amounting to $84.5 billion, surpassing the total of over $60 billion for 2024. Hengrui Medicine's international deals included partners like GSK and Merck, with upfront payments totaling $765 million [3] Group 3: Market Challenges - Some companies that previously entered the billion-dollar club, such as Kintor Pharmaceutical and China National Pharmaceutical Group, have fallen below the threshold due to systemic valuation corrections and stricter FDA approval standards [4] - The market has become desensitized to BD transactions, as evidenced by the stock price drop of Innovent Biologics following a $11.4 billion collaboration announcement, indicating a tightening of valuation expectations [4] Group 4: Capital Operations - As the innovative drug market heats up in 2025, companies are initiating new capital operations, including acquisitions and cross-border listings. For instance, China National Pharmaceutical Group acquired Lixian Pharmaceuticals for approximately $500 million [5] - Baillie Gifford raised 3.764 billion yuan through a private placement in the A-share market, while also applying for an IPO in Hong Kong [5] Group 5: Small-cap Stocks - The top three performing innovative drug stocks in A-shares for 2025 were Shuyou Pharmaceutical (涨幅488%), Yipinhong (涨幅370%), and Yifang Biotechnology (涨幅235%). In H-shares, the top performers were Beihai Kangcheng (涨幅1824%), Heber Pharmaceuticals (涨幅553%), and Sanofi (涨幅311.18%) [7] - These stocks have core products that received high recognition, with clinical pipelines achieving significant breakthroughs, such as Shuyou's STSP-0601 and Beihai Kangcheng's Selinexor [7] Group 6: Future Outlook - The innovative drug sector is expected to enter a "hardcore alpha" phase in 2026, focusing on companies that can deliver genuine clinical data, achieve overseas commercialization, and demonstrate domestic profitability [10] - The emphasis will shift from broad market rallies to specific companies that can prove their clinical trial results and secure sales milestones, with a focus on high-demand areas like dual antibodies and ADCs [11][12]

Market Overview - The Shanghai Composite Index closed at 4120.10 points, above the annual line, with a change of 0.16% [1] - The total trading volume of A-shares reached 1,645.83 billion yuan [1] Stocks Above Annual Line - A total of 61 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Huawi Design (华维设计) with a deviation rate of 24.42% - Hualing Co. (华岭股份) at 5.51% - Huilong Piston (汇隆活塞) at 4.81% [1] Detailed Stock Performance - The following table summarizes the performance of selected stocks that have crossed the annual line: - Huawi Design (华维设计): Today's change of 29.96%, turnover rate of 26.39%, annual line at 14.64 yuan, latest price at 18.22 yuan [1] - Hualing Co. (华岭股份): Today's change of 12.70%, turnover rate of 9.21%, annual line at 24.90 yuan, latest price at 26.27 yuan [1] - Huilong Piston (汇隆活塞): Today's change of 18.06%, turnover rate of 13.30%, annual line at 9.86 yuan, latest price at 10.33 yuan [1] - Other notable stocks include: - Wuhan Fangu (武汉凡谷) with a deviation rate of 4.17% - Meirui New Materials (美瑞新材) with a deviation rate of 3.81% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Gongdong Medical (拱东医疗) and Chongqing Gas (重庆燃气) [1] - The performance of these stocks indicates a cautious upward trend in the market [1]

Core Insights - The global growth factor drug market is steadily increasing, projected to grow from 13.2 billion in 2018 to 15.9 billion by 2025, with a compound annual growth rate (CAGR) of 3.4% [8][9] - The Chinese growth factor drug market is recovering, expected to reach 7.1 billion by 2025, doubling from 2020 levels, driven by the introduction of more human-derived products and expanded indications [9][10] - The market is characterized by a diverse range of growth factor products, with FGF holding the largest market share, followed by EGF and NGF [10] Growth Factor Drug Industry Overview - Growth factors are bioactive substances that regulate cell proliferation, migration, survival, and differentiation during tissue repair by binding to specific receptors on cell membranes [2][3] - They operate through paracrine and endocrine mechanisms, influencing local and systemic physiological processes [2][6] Market Status - The global growth factor drug market is expected to exceed 20 billion by 2029, indicating a robust growth trajectory [8] - In China, the market experienced a decline from 2019 to 2020 due to concerns over non-human-derived products and stricter regulations, but is now on a recovery path [9][10] Product Approval Status - As of December 2025, 38 growth factor drugs are expected to be approved in China, with significant contributions from companies like Zhuhai Yisheng Biopharmaceutical and Beijing Shuanglu Pharmaceutical [10][11] Development Trends - The growth factor drug market is anticipated to grow due to increasing demand for treatments in open wound care, ophthalmic diseases, and nerve regeneration [11] - Expanding indications and supportive policies are expected to accelerate new drug development and approval processes [11]

Group 1 - The core viewpoint of the news is that Shuyou Shen's stock has shown a significant increase in price recently, with a year-to-date increase of 10.65% and a notable rise of 10.65% over the last five trading days [1] - As of January 9, Shuyou Shen's stock price reached 30.23 yuan per share, with a total market capitalization of 14.443 billion yuan [1] - The company primarily engages in the research, production, and sales of biological products and certain chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] Group 2 - As of September 30, the number of shareholders for Shuyou Shen increased by 46.97% to 46,500, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million yuan, a decrease of 227.71% [2] - The company has distributed a total of 771 million yuan in dividends since its A-share listing, but has not paid any dividends in the last three years [3]

（文章来源：证券日报） 证券日报网讯 1月7日，舒泰神在互动平台回答投资者提问时表示，公司预计将于2026年1月31日前发布 2025年年度业绩预告。 ...

Summary of Key Points Core Viewpoint - The stock of Shuotai Shen experienced a 2.25% increase, closing at 29.49 yuan, with significant block trades occurring on January 7, totaling 500,000 shares and 13.265 million yuan in transaction value [1] Block Trade Details - The first block trade occurred at a price of 26.53 yuan for 115,000 shares, amounting to 3.051 million yuan, with a discount rate of -10.04% [1] - The second block trade also took place at 26.53 yuan for 154,000 shares, totaling 4.086 million yuan, maintaining the same discount rate of -10.04% [1] - The third block trade was for 231,000 shares at 26.53 yuan, resulting in a transaction value of 6.128 million yuan, again with a discount rate of -10.04% [1] Recent Trading Activity - Over the past three months, Shuotai Shen has recorded five block trades with a cumulative transaction value of 94.5263 million yuan [1] - In the last five trading days, the stock has risen by 5.96%, while the net outflow of main funds amounted to 77.9453 million yuan [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2026-01-07 | 300204 | 舒泰神 | 26.53 | 11.50 | 305.10 机构专用 | | 东吴证券股份有限 | | | | | | | | | 公司太仓上海东路 | | | | | | | | | 证券营业部 | | 2026-01-07 | 300204 | 舒泰神 | 26.53 | 15.40 | 408.56 机构专用 | | 东吴证券股份有限 | | | | | | | | | 公司太仓上海东路 | | | | | | | | | 证券营业部 | | 2026-01-07 | 300204 | 舒泰神 | 26.53 | 23.10 | 612.84 机构专用 | | 东吴证券股份有限 | | | | | | | | | 公司太仓上海东路 | | | | | | | | | 证券营业 ...

证券代码：300204 证券简称：舒泰神 公告编号：2026-001 舒泰神（北京）生物制药股份有限公司 关于公司拟向银行申请贷款并提供抵押反担保的进展公告（二） 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"）预计 对合并报表外单位提供担保额度超过公司最近一期经审计净资产的 30%。本次预 计担保额度并非实际担保金额，实际担保金额尚需以实际签署并发生的担保合同 为准。敬请投资者注意相关风险。 一、抵押反担保情况概述 舒泰神（北京）生物制药股份有限公司于 2025 年 11 月 06 日召开第六届董 事会第十一次会议，并于 2025 年 11 月 24 日召开 2025 年第三次临时股东会，审 议通过了《关于公司拟向银行申请贷款并提供抵押反担保额度预计的议案》，公 司拟新增向上海浦东发展银行股份有限公司北京分行、北京农村商业银行股份有 限公司经济技术开发区支行、广发银行股份有限公司北京东四环支行、交通银行 股份有限公司北京自贸试验区支行等商业银行申请贷款合计不超过 20,000 ...